文献速递脑血管病

神经血栓切除装置治疗急性缺血性卒中的系统评估:STRATIS登记研究主要结果

Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke: Primary Results of the STRATIS Registry.
PubMed 文献 · Stroke · 2017-08-22

STRATIS是一项前瞻性美国多中心登记研究,纳入984例在症状发作8小时内接受Solitaire取栓装置治疗的急性缺血性卒中患者,并与SEER荟萃分析介入队列比较。结果显示87.9%患者达到mTICI≥2b再灌注,90天56.5%达mRS 0-2,死亡率14.4%,症状性颅内出血1.4%,证实随机试验结果可在真实世界重现,但获益随转运时间延迟而下降。

要点

  • 真实世界取栓再灌注率87.9%,90天良好功能预后56.5%
  • 院前到穿刺每延迟1小时,mRS 0-2可能性绝对下降5.5%
  • 症状性颅内出血率仅1.4%,安全性与随机试验一致

核心结论

  • 迄今最大规模Solitaire登记研究证明随机试验结果可在社区医院重现。
  • 临床获益随时间延迟而下降,需优化救治体系。

研究设计与样本

  • 前瞻性美国多中心登记研究,55个中心共纳入984例患者。
  • 纳入症状发作8小时内接受Solitaire及Mindframe取栓装置治疗者。
  • 与已发表SEER患者水平荟萃分析的介入队列进行比较。

主要发现

  • 平均NIHSS评分17.3,64.0%接受静脉tPA治疗。
  • 发病至入院中位138分钟,入院至穿刺72分钟,穿刺至再灌注36分钟。
  • 核心实验室判定mTICI≥2b达87.9%。
  • 90天mRS 0-2为56.5%,全因死亡率14.4%,症状性颅内出血1.4%。
  • 急救现场到达至穿刺中位152分钟,每延迟1小时mRS 0-2可能性绝对下降5.5%。

关键数值与推荐

  • mTICI≥2b再灌注率87.9%。
  • 90天mRS 0-2比例56.5%。
  • 全因死亡率14.4%,症状性颅内出血1.4%。
  • 院前至穿刺每延迟1小时,mRS 0-2绝对下降5.5%。

临床怎么用

  • 真实世界取栓应追求与随机试验一致的再灌注和功能预后。
  • 应优化院前转运与院内流程以缩短穿刺时间。
  • 时间延迟显著削弱临床获益,需建立高效救治体系。

局限性

  • 原文摘要未报告随机对照设计,为单臂登记与历史队列比较。
  • 仅纳入使用特定装置且8小时内治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Mechanical thrombectomy with stent retrievers has become standard of care for treatment of acute ischemic stroke patients because of large vessel occlusion. The STRATIS registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) aimed to assess whether similar process timelines, technical, and functional outcomes could be achieved in a large real world cohort as in the randomized trials. METHODS: STRATIS was designed to prospectively enroll patients treated in the United States with a Solitaire Revascularization Device and Mindframe Capture Low Profile Revascularization Device within 8 hours from symptom onset. The STRATIS cohort was compared with the interventional cohort of a previously published SEER patient-level meta-analysis. RESULTS: A total of 984 patients treated at 55 sites were analyzed. The mean National Institutes of Health Stroke Scale score was 17.3. Intravenous tissue-type plasminogen activator was administered in 64.0%. The median time from onset to arrival in the enrolling hospital, door to puncture, and puncture to reperfusion were 138, 72, and 36 minutes, respectively. The Core lab-adjudicated modified Thrombolysis in Cerebral Infarction ≥2b was achieved in 87.9% of patients. At 90 days, 56.5% achieved a modified Rankin Scale score of 0 to 2, all-cause mortality was 14.4%, and 1.4% suffered a symptomatic intracranial hemorrhage. The median time from emergency medical services scene arrival to puncture was 152 minutes, and each hour delay in this interval was associated with a 5.5% absolute decline in the likelihood of achieving modified Rankin Scale score 0 to 2. CONCLUSIONS: This largest-to-date Solitaire registry documents that the results of the randomized trials can be reproduced in the community. The decrease of clinical benefit over time warrants optimization of the system of care. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02239640.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mueller-Kronast NH, Zaidat OO, Froehler MT, et al. Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke: Primary Results of the STRATIS Registry. Stroke. 2017. PMID: 28830971. doi:10.1161/STROKEAHA.117.016456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。